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Antitumour Activity, Toxicity and Inhibition of 
Thymidylate Synthase of Prolonged 
Admihistration of 5Fluorouracil in Mice 
G. Codacci-Pisanelli, C.L. van der Wilt, H.M. Pinedo, F. Franchi, 
P. Noordhuis, B. J.M. Braakhuis, J.A.M. van Laar and G. J. Peters 
Continuous infusions of 5-fluorouracil (S-FU) are increasingly used in the treatment of cancer. Their optimal use, 
however, has still to be determined since the availability of suitable animal models is limited. We studied 
continuous infusions in mice using subcutaneously implanted pellets that release S-FU over a period of 3 weeks. 
At the maximum tolerated dose (MTD) (based on the systemic toxicity in healthy animals) we assessed the 
antitumour activity, haematological toxicity, inhibition of thymidylate synthase (TS) in tumours and the 
concentration of S-FU in plasma during the 3-week period. We also studied the addition of leucovorin in different 
schedules. The dose-limiting toxicity was weight loss, and at the MTD of 10 mg of S-FU released in 21 days per 
mouse myelosuppression was tolerable (nadir for leucocytes and thrombocytes was approximately 40% of 
pretreatment levels). In several independent experiments using the S-FU-resistant Colon 26 tumour, a good 
antitumour acitivity was observed during the first part of the infusion, but thereafter the growth of the tumours 
resumed; the overall effect of continuous infusions was thus comparable to that of bolus injections. Co- 
administration of leucovorin did not enhance the therapeutic results; depending on the schedule used, it proved 
ineffective or only increased toxicity. Similar results were obtained with head and neck squamous cell carcinomas 
and with the S-FU-sensitive tumour Colon 38. In Colon 26 tumours the TS activity (FdUMP-binding assay) 
initially decreased to 2&,30% of controls and returned to normal after 11 days. In the catalytic TS assay a slight 
inhibition was observed for the continuous infusion, followed after 11 days by a marked (4-fold) increase in 
activity. 5-FU plasma levels varied from 0.1 to 1 PM following a circadian rhythm (with a peak at 6 h after light 
onset), and were maintained during the entire period. Subcutaneously implanted pellets represent a suitable 
model to study prolonged administration of S-FU in mice and to evaluate the effect of modulating agents in 
laboratory animals before transferring data obtained in vitro to the clinic. 
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INTRODUCTION 
S-FLUOROURACIL (5-FU) has been used for more than 30 years 
for the treatment of cancer, but even though this is one of the 
most widely employed drugs in clinical oncology, the most 
effective schedule has yet to be established [l-5]. A daily bolus 
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for 5 consecutive days, one weekly injection, and prolonged 
infusions have been employed, but with no clear differences in 
antitumour acitivity for the different modalities of adminis- 
tration [6]. The pattern of toxicity, however, varies for the 
different schedules. The dose-limiting toxicity for bolus injec- 
tions is myelosuppression, while for continuous infusion gastro- 
intestinal toxicity is prominent; mucositis and diarrhoea can 
be severe, and at times life-threatening, while the hand-foot 
syndrome is almost exclusively observed with prolonged 
infusions [ 7-91. 
The potential use of S-FU continuous infusion has been 
known for many years: pharmacokinetic and in tirrodata support 
the concept hat a constant exposure is more effective than bolus 
administration even if plasma concentrations with continuous 
infusion are lower. When cells in culture are treated for a 
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prolonged period of time the drug shows more activity than in a 
1 h exposure followed by culture in drug-free medium [ lO-141. 
In cell lines the 50% growth inhibiting concentration (IQ,,,) of 5- 
FU for a 1 h exposure is approximately 300 ~J,M, while for 
24-72 h exposure it is 2-10 ~.LM. Continuous exposure leads to 
the constant presence of the active metabolite FdUMP in 
relatively high concentrations [3] so that the inhibition of 
thymidylate synthase (TS), the target of FdUMP, is facilitated. 
[3H]-dUMP (specific activity 10.9 Ci/mmol) from Amersham 
International (Buckinghamshire, U.K.). dl-Tetrahydrofolate 
(Sigma Chemicals Co., St Louis, Missouri, U.S.A.) was con- 
verted into 5, lo-methylenetetrahydrofolate by addition of for- 
maldehyde [ 121. All other chemicals were of analytical grade and 
are commercially available. 
In vivo studies 
During 
5-FU exposure the enzyme was inhibited but its activity reco- 
vered when the drug was removed [ 15, 161. Previously we 
obtained convincing evidence that in a murine model for colon 
carcinoma, Colon 26, the relatively poor inhibition of TS and its 
retention was associated with the limited antitumour effect of S- 
FU but that modulation by leucovorin (LV) enhanced TS 
inhibition and the antitumour activity [ 171. In vim experiments 
showed that, during prolonged exposure of cells to 5-FU, 
cytotoxicity was due to inhibition of TS while the effect on RNA 
was prominent during short-term exposure to high concen- 
trations of the drug [ 161. 
Female, Balb/c, C57/Bl and athymic nude mice (NMRI) 
of 8-10 weeks were obtained from HarlanCpb (Zeist, The 
Netherlands) and were maintained in the Clinical Animal Lab- 
oratory of the Free University. All experiments were performed 
in accordance with the rules for animal welfare established by 
this institution. Toxicity studies were carried out in healthy 
female C57/Bl and Balb/c mice. Parameters used to deiine the 
MTD were weight loss not greater than 15% and/or lethality 
less than 10%. Investigations on haematological toxicity were 
performed as previously described in detail [28-301. Blood 
sampling was performed by retro-orbital puncture with hep- 
arinised capillaries after slight ether anaesthesia [25]. 
The efficacy of 5-FU during continuous infusion may be 
influenced by the circadian behaviour of levels of plasma 5-FU 
[H-20], which are related to the diurnal variations in the levels of 
the 5-FU-degrading enzyme, dihydropyrimidine dehydrogenase 
(DPD) [ 19, 2 11. In mice, rats and humans evidence is accumulat- 
ing that various enzymes involved in 5-FU metabolism, such as 
DPD, uridine phosphorylase and thymidine kinase have a 
circadian rhythm [21-241. Such variations in enzyme activity 
have not been related to plasma 5-FU concentrations during 
continuous infusion of 5-FU alone. 
Optimisation of continuous infusion of 5-FU requires the 
availability of suitable animal models. Although continuous 
exposure of cells to 5-FU in v&o is more effective than pulse 
exposure, in vitro models lack the possibility of investigating the 
pharmacodynamics of bolus and continuous infusion of 5-FU; 
e.g. the selectivity of both protocols cannot be evaluated. Other 
factors which cannot be studied in tirro are the possible effects 
of circadian variations and accumulation of the drug in tissues. 
Recently, we demonstrated that plasma 5-FU levels do not 
reflect tissue levels [25]. Prolonged continuous infusions are 
complex to perform in small animals: a venous access is difficult 
to maintain even for a relatively short time and other devices for 
continuous infusions including implantable osmotic pumps are 
only effective for a few days [26, 271. Long-term infusions in 
small animals can best be carried out by means of slow-release 
forms of 5-FU. 
Antitumour activity was studied on the murine colon carci- 
nomas Colon 26 maintained in female Balb/c mice, Colon 38 
maintained in C57Bl mice and on xenografts of the human 
squamous cell carcinomas of the head and neck, HNX-14C and 
HNX-OE, maintained in nude mice. Tumours were trans- 
planted subcutaneously in the thoracic region on each flank of 
the animal [28-311. Tumour size was measured sequentially 
twice weekly using a call&r, and the volume was calculated as 
length x width x height x 0.5. The evaluation of antitumour 
activity was based on the following parameters: the ratio of the 
mean volume of treated tumours and the mean volume of control 
tumours (T/C); the increase in the life span (ILS) defined as the 
ratio (X 100%) of the median life span (MLS) of treated mice 
divided by the MLS of controls (MLS is measured starting from 
the first day of treatment); the growth delay factor (GDF) 
calculated from the median tumour doubling time (TD) of the 
tumours of treated mice and control mice according the following 
formula: 
GDF = (TDtrePted - TD,,,,JTD,,,,,. 
TDcont,o,s i  about 3 days for Colon 26, 5 days for Colon 38, 4 
In the experiments described in this paper we have used 
pellets containing 5-FU that are implanted subcutaneously and 
release the drug for several weeks. We have characterised 
the maximtmr tolerated dose (MTD), plasma levels, toxicity, 
antitumour activity and effect on the target enzyme of 5-FU 
given as a continuous administration using subcutaneous pellets. 
We have also examined the possibility of modulating 5-FU 
activity with LV given in different doses and schedules. 
days for HNX-OE and 8 days for HNX-14C. For toxicity and 
antitumour activity studies, 5-FU pellets containing different 
amounts of drug (5, 10, 15, 20 mg) were implanted subcutane- 
ously on the back of mice after ether anaesthesia. Care was taken 
to avoid any direct contact of the pellet with the turnour even 
when this had grown to its maximum size. Bolus 5-FU was 
administered i.p. at the MTD: 100 mg/kg i.p. for Balb/c and 
C57/Bl mice and 125 mgikg for nude mice. Leucovorin was 
injected intraperitoneally (i.p.) according to the doses and 
schedules indicated in the experiments. Treatment was started 
when the tumours had reached a size of 50-150 mm3 
(approximately 10 days for Colon 26, 18 days for Colon 38, 16 
and 24 days for HNX-14C and HNX-OE, respectively). 
Ch.?micals 
MATERIALS AND METHODS 
Enzyme assays 
5-FU for bolus injections was obtained from ABIC (Netanya, Tumours were removed at different time points after pellet 
Israel). 5-FU pellets were purchased from Innovative Research implantation, or from untreated controls, and were immediately 
of America (Toledo, Ohio, U.S.A.). Leucovorin was provided frozen in liquid nitrogen. TS assays, FdUMP binding assay and 
by the Pharmacy department of the Free University Hospital. 6- 3H-release assay, were performed as described [17]. The frozen 
[3H]-FdUMP (specific activity 20 Ci/mmol) was purchased from tissues were pulverised by means of a microdismembrator 
Moravek Biochemical Inc. (Brea, California, U.S.A.) and 5- (Braun, Melsungen, Germany) and the frozen powder was 
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suspended in a Tris-HCI buffer (200 mM) containing 
20 mM P-mercaptoethanol toincrease the stability of disulphate 
bonds present in the TS molecule and 100 mM NaF and 15 mM 
CMP to inhibit the breakdown of nucleotides. Temperature was 
maintained at 4°C and pH at 7.4. The suspension was centrifuged 
at 4000 g and the supernatant subsequently at 7000 g. The 
enzyme-containing suspension was split in several parts and 
used for different assays. Details have been described previously 
r171. 
Briefly, the first assay was a ligand-binding assay with 6-[3H]- 
FdUMP as the substrate, used to determine the free FdUMP 
binding sites of TS. Enzyme suspension (50 l.~l) was mixed with 
50 l~,l 6.5 mM CH,-THF, 135 ~1 Tris-HCl buffer and the 
reaction was intitiated by addition of 15 p.1 570 nM 6-[3H]- 
FdUMP; the mixture was incubated at 37°C for 1 h, stopped by 
addition of 500 p.1 10% neutral charcoal, vigorously mixed, 
chilled on ice and centrifuged. Radioactivity was estimated by 
liquid scintillation counting of 250 l.~l supematant. 
The second assay determines the catalytic activity of TS at a 
final concentration of 1 and 10 FM 5-[3H]-dUMP by means of 
the 3H-release. The TS catalytic activity assay in control tumours 
consisted of: 25 ~1 enzyme suspension (at different dilutions), 
5 p,l 6.5 mM CH2-THF, 110 ~1 Tris-HCl or 10 l.~l 0.05 (LM 
FdUMP to measure the potential inhibition of TS in control 
samples. The assay was initiated by addition of 10 ~1 5-r3H]- 
dUMP (1 or 10 p,M final concentration) and was incubated for 
30 min at 37°C stopped by addition of 50 ~1 ice cold 35% 
trichloroacetic acid and 250 p,l 10% neutral activated charcoal. 
After centrifugation, 150 ~1 of the supernant was counted by 
liquid scintillation [ 171. 
Before the assays were performed, endogenous FdUMP and 
other nucleotides were removed with activated neutral charcoal 
in samples from treated animals. This charcoal wash was also 
performed on control samples and did not change the results of 
the assays. In a number of samples both the total amount of TS 
and the residual TS activity were measured. For this purpose, 
assays were only performed after a dissociation step. One part of 
the enzyme suspension was used for dissociation of FdUMP 
from TS, by incubation of equal volumes of the enzyme suspen- 
sion and dissociation buffer ((0.75 M NH&04, 100 mM NaF, 
20 mM B-mercaptoethanol, 1.5 mM CMP, pH 7.8) and l/20 of 
the total volume of 1.6 mM dUMP for 3 h at 30°C. The 
high concentration of dUMP facilitated dissociation, prevented 
reassociation of FdUMP and stabilised TS. Addition of 10% 
neutral charcoal (same volume as the total dissociation volume) 
was used to remove the nucleotides after dissociation. An equal 
volume of the enzyme suspension was frozen at -70°C and 
thawed after 3 h. This part of the enzyme suspension was also 
treated with 10% neutral charcoal. Both assays of TS were 
performed in the dissociated and non-dissociated samples, 
enabling determination of the total and free number of FdUMP 
binding sites, respectively, and the total and residual catalytic 
activity, respectively. Protein content of the turnouts was assayed 
using the BioRad protein assay. 
Analysis of 5-FU and FdUMP levels 
Plasma concentrations of 5FU were measured in healthy 
female C57/Bl mice: blood was drawn retro-orbitally between 
9.00 a.m. and 10.00 a.m., 3-4 h after light onset (HALO), in 
order to avoid circadian variability. Differences in concen- 
trations at various time points: were studied on day 10, when 5 
animals were sampled at six time points from 3 HALO until 15 
HALO (8 h dark, 16 h light). IBlood was centrifuged and plasma 
samples were immediately frozen. 5-FU concentration was 
measured by gas chromatography coupled to mass-spectrometry 
(G-MS) as previously described [25, 321. The sensitivity and 
selectivity of this analytical procedure enables the use of very 
small samples (10 ~1): in this way every animal could be sampled 
repeatedly during the 3 weeks and a complete pharmacokinetic 
profile was obtained for each animal. In order to exclude the 
possibility that pellets were exhausted after a few days from 
implantation, some pellets removed from several mice after 
10 days were implanted in different mice and plasma concen- 
tration was measured during the following period. 5-FU and 
FdUMP concentrations were also measured in Colon 26 tumours 
during the infusion at different times after implantation of the 
pellet. Tissues were removed during anaesthesia nd immedi- 
ately frozen in liquid nitrogen. 5-FU and FdUMP concentrations 
were measured as described previously [ 17, 251. 
RESULTS 
Toxicity 
The extent of systemic toxicity was expressed as percentage of 
weight loss following the implantation of the pellet. Pellets 
containing different amounts of 5-FU were studied in healthy 
mice; larger pellets (15 and 20 mg) caused an important loss of 
weight (approximately 25% at day 4) and proved rapidly fatal, 
while weight loss was 11% at day 11 following implantation of 
10 mg pellets (Figure 1). The pattern of systemic toxicity 
differed from that of bolus injections [28]: weight loss was not 
seen in the first days after the beginning of treatment, but after 
10 days, and the maximum weight loss during continuous 
infusions was higher than that observed after bolus injection. 
Similar data on toxicity were obtained in tumour-bearing animals 
(Table 1). 
Pellets containing 10 mg 5-FU, released over 3 weeks were 
considered to be the MTD for this form of therapy, and these 
pellets have been used for all the following studies unless 
otherwise indicated. The additional effect of LV was investigated 
at various doses and schedules. A weekly bolus injection of 
100 mg/kg had no effect, but small daily doses of 5 mgikg 
resulted in severe diarrhoea, major weight loss and increased 
mortality (Table 1). 
The pattern of haematological toxicity of 5-FU pellets has 
been studied in healthy mice at the MTD of 10 mg per mouse 
(Figure 2a-c). Haematocrit (Figure 2a) reached a nadir of 70% 
110 r 
Systemic toxicity of 5-FU 
I I I I I I I 
0 4 8 12 16 20 24 
Days after treatment s art 
Figure 1. Systemic toxicity of S-FU given as an i.p. bolus injection 
(given on days 0 and 7) or as a continuous infusion. The weight is 
expressed as a percentage of the initial value. The doses and sched- 
ules of S-FU were 100 &g/kg i.p. bolus (-0-), 10 mg pellets (-A-), 
15 mg pellets (-A-). The curve for 20 mg pellets is superimposed on 
that of the 15 mg pellets. Values are means 2 S.E. of >S mice. 
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Table 1. Antitumour activity of 5-FU bolus and continuous infusions 
S-FU Dose LV Schedule@ Max. weight loss T/C GDFt 
Median lifespan$ Increase of 
(days) lifespan+ (%) 
Colon 26 
lOOmg/kg - 
Smg - 
10mg - 
100 mgikg 100 mgikg 
1Omg 100 m&g 
10mg 5 mg/kg 
10mg 10 mg/kg 
1Omg 20 mg/kg 
1Omg 10 mg/kg 
Colon 38 
100 mg/kg 
10 mg 
HNX-OE 
10 mg 
HNX-14c 
125 mg/kg 
10 mg 
2 
2 
7 11 0.59 1.7 47 n.e.1 
2 7 0.62 1.0 44 n.e.7 
6.0 2 2.0(9)§ 0.51 2 0.14(9)9 
6.2 0.39 
3.8 2 2.1(6) 0.34 f 0.09 (6)** 
6.2 2 1.7(7) 0.42 2 O.ll(7) 
5.4; 5.9 0.28; 0.35 
3.7 0.21 
8.7 0.44 
5.6 0.40 
5.3 0.34 
4.7 2 1.9 (5) 0.13 -c 0.02 (5) 
20.6 0.01* 
10 0.42 2.9 >46 
0.9 -+ 0.4 (9)s 25 (9)s 
2.2 23 
2.1 -t 0.7 (S)*** 24 (6) 
2.2 f 0.7 (7)*** 26 (7) 
2.2; 2.7 18; 27 
n.e.t 17 
n.e.t 20 
n.e.t 20 
2.7 19 
2.5 5 0.9 (5) > so (5) 
3.5 > so 
169 -+ 57(9)9 
143 
161 2 32(6) 
171 -r- 66 (7) 
120; 93 
100 
67 
67 
150 
n.e.11 
n.e.// 
n.e.7 
@Schedules: (1) Weekly i.p. bolus injection S-FU, 4 X; (2) Continuous infusion S-FU with pellet during 21 days; (3) S-FU as in (l), LV, 2 split 
doses of SO mg/kg i.p. given 1 h before and together with S-FU, weekly 4 X; (4) S-FU as in (2), LV, weekly i.p. bolus injection, 4 x ; (5) S-FU as in 
(2), LV, daily i.p. bolus injection 5 days a week for 3 weeks; (6) S-FU as in (2), LV, every other day i.p. bolus injection (3 days a week for 3 weeks; 
(7) Weekly i.p. bolus injection S-FU, 2 X; jn.e. not evaluable because no tumour doubling was reached; $the median lifespan was calculated 
starting from the day of tumour implantation; the median lifespan of control mice (starting from the day of first treatment) is set at 100%; $The 
number in the parentheses is the number of experiments with at least 6 mice. The data where no n is mentioned are from one experiment with at 
least 6 animals. T/C is given for day 7 for Colon 26 and Colon 38, and day 10 for HNX-OE and HNX-14C; IlLifespan is not assessed for mice bearing 
this tumour, they were sacrificed when tumour load exceeded 2000 mm3; l/Lifespan was not assessed for mice bearing this tumour, they were 
sacrificed when turnour load exceeded 1500 mm3. Significantly different from the bolus injections (test for unpaired samples) at the level of: 
0.02 < P < 0.05 (*); 0.01 < P < 0.02 (**) and P < 0.01 (***). Maximum weight loss is expressed as a percentage of the initial weight. 
of initial values after 7 days and it returned to normal levels after 
20 days, coinciding with the end of the infusion. The effect on 
granulocytes was characterised by a 600/o decrease after 4 days 
compared with pretreatment levels (Figure 2b). However, this 
was followed by a marked rebound after about 20 days, and by 
the return to normal levels after discontinuation of the 5-FU 
release. The initial effect on thrombocytes (Figure 2c) was 
comparable to that on total white blood cells, but only a moderate 
rebound was observed. Animals in which only the carrier 
material of the pellet was implanted and untreated controls 
showed no significant changes in white blood cell counts or in 
haematocrit. A late effect of sampling was observed on the 
thrombocyte counts; however, the effect of 5-FU treatment was 
immediate and more pronounced, and cannot, therefore, be 
attributed to sampling. 
Antitumour activity of continuous infusion S-FU with and without 
leucovorin 
The therapeutic effect of pellets at the MTD was compared 
with that of “standard” 5-FU treatment, consisting of weekly 
bolus injections i.p. at the MTD of 100 mg/kg. Figure 3 shows 
a typical growth curve for Colon 26. A bolus injection of 5-FU 
induced a reduction in growth rate but continuous infusion 
actually blocked tumour development for about 1 week. How- 
ever, thereafter, the tumour started to grow at the same rate as 
the untreated controls. The 10 days growth inhibition followed 
by regrowth was also observed in Colon 38, HNX-14C and 
HNX-OE. The overall results in terms of survival and growth 
delay factor of bolus injections and continuous infusion were 
similar, both for Colon 26 and for the other tumours (Table 1). 
Using a lower dose (5 mg pellets) the tumour growth was 
blocked for only 3 days and then resumed. 
Previously we demonstrated that the antitumour activity of 
bolus 5-FU against Colon 26 could be potentiated by LV 
[17, 301. Therefore, we combined continuous infusion 5-FU 
with LV in different schedules. A single weekly bolus injection 
had no effect at all, nor did administration of LV in different 
schedules, three times a week and daily administration. The 
overall therapeutic efficacy of the combination of continuous 
infusion 5-FU and LV was not different from 5-FU continuous 
infusion alone. Tumour volumes exhibited a plateau phase of 
about 7 days followed by rapid regrowth (Figure 3). 
Analysis of plasma concentrations 
In order to assess whether 5-FU was released at a constant rate 
we determined the plasma concentrations over 3 weeks. The 
10 mg dose delivered by the pellets corresponds to a daily dose 
of 23.8 mg/kg 5-FU (assuming a mouse of 20 g) which results in 
a higher cumulative dose than with weekly bolus injections 
(166 versus 100 mg/week). Plasma 5-FU concentrations at 94 
HALO were in the range of 0. l-l FM and were maintained for 
3 weeks (Figure 4a). Plasma levels tended to decrease after 
16 days, but 5-FU concentrations remained above the detection 
limit of the assay for 21 days. In the following period the drug 
was undetectable in plasma, which indicated that release was 
completed. Similar plasma concentrations were found in mice 
that were implanted with pellets removed from another mouse 
(Figure 4a). 
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Days after pellet implantation 
Figure 2. Haematological toxicity of 10 mg 5-FU pellets io C57IBl 
mice: (a) haematocrit, (b) leucocytes, (c) platelets. Values for controls 
(-0-) and pellet treatment (-A-) were expressed as a percentage of 
initial values calculated per individual mouse. Initial values are 
means QS.D.) of 20 mice: haematocrit, 47.5% (k 3.8); leucocytes, 
3.9 X lQ(lr 1.1 X 106)ceUs/u~platelets, 1413 X lC(lr 550 X 1P) 
cells/ml. Values at other time points are means f S.D. of at least 3 
mice. Student’s t-test for paired data: (a) haematocrit of treated mice 
is sigailicaatly lower than before treatment at days 4-14 (P CO.01). 
(b) After 47 days the number of leucocytes of treated mice was 
sigai6cantly lower than before treatment (P <0.05). At day 18 the 
number was signilicaotly higher than before treatment (P <O.Ol). (c) 
The number of platelets of treated mice was significantly lower tbao 
before treatment at day 4 (P <:0.05). At day 12 it was significantly 
higher tbao before treatment (P <0.05). 
We also measured plasma concentrations at different time 
points during the day after 10 days from the implantation of 
pellets. A IO-fold difference between the plasma concentration 
at 3 HALO and the peak value at 6 HALO was consistently 
observed in each animal. At 12 HALO and later, plasma 5-FU 
concentrations were generally undetectable (Figure 4b). Peak 
and trough values were sign% candy different from the calculated 
means. 
I 1 I I I I I 
2 4 6 8 10 12 14 
Days of treatment 
Figure 3. Relative antitumour activity on Colon 26 of 100 mgkg 
bolus 5-FLJ (-O-) 10 mg 5-FU pellets (-A-), 10 mg 5-FU pellets 
combined with 5 mgkg LV given as 5 daily bolus injections (-V-) 
compared with controls (-A-). Values are means * S.D. of 3-6 mice 
(6-12 tumours). 
(a) 04 
.r 
J 
4 8 12 16 20 24 
Days from pellet implantation 
b 
15 
HALO 
Figure 4. (a) 5-FU plasma concentration in C57/Bl mice at 3-4 
HALO (mean values k S.D. of at least three values). (-Cl-); values 
from one of the pellets that was implpntea in one mouse and aRer 10 
days was moved to another (4). (b) Circadian variation studied on 
day 10 from pellet implantation, data are showa for each separate 
animal. Tie is measured as hours after light onset (HALO): 3 HALO 
corresponds to 9.00 a.m. Student’s t-test for paired dataz plasma 
concentration at 12.00 (6 HALO) was significaatly different from all 
other time points (P CO.01). 
1522 G. Codacci-Pisanelli et al. 
During the infusion we also measured 5-FU concentration in 
tumours (Figure 5). The highest concentrations were observed 
at the beginning of the infusion. At all time points 5-FU 
concentrations in the tumour were at least 2-fold higher than the 
corresponding levels in plasma. 
FdUMP concentrations and effect on TS 
The concentrations of FdUMP were measured in tumours at 
various time points after implantation of the pellets. However, 
at all time points the FdUMP concentrations were below the 
detection limit (12 pmol/g wet weight) of the assay. Despite 
the low levels of FdUMP, the activity of TS was inhibited 
significantly during the first week (Figure 6a, b). The number 
of free FdUMP binding sites was reduced signilicantly at days 4 
and 7 after the start of treatment. However, after 11 days a 
partial recovery was observed, followed by a complete recovery 
to normal levels after 2 weeks. The catalytic activity of TS 
showed a somewhat different pattern with a small decrease in 
the residual TS activity after 4 and 7 days and a comparable total 
TS catalytic activity. After 11 days a 3-fold increase in TS 
residual catalytic activity was accompanied by an almost 5-fold 
increase in the total catalytic activity. Thereafter, the total 
catalytic activity decreased and was comparable on the residual 
activity after 14 days. 
DISCUSSION 
Continuous infusion of 5-FU has a considerable interest in the 
clinic. In this paper we show that it is feasible to administer 5- 
FU continuously over 3 weeks to mice attaining plasma levels 
that are comparable to those observed during continuous 
infusions in patients [33-381 and in rats [39], although in the 
latter species, and in some of the studies in patients, infusions 
were shorter. During limited infusion periods (3-7 days), plasma 
concentrations tended to be higher than in longer infusions 
(21 days) possibly due to the higher dose which could be 
administered. The overall results, both antitumour activity and 
toxicity, are also in agreement with the clinical data [7, 81, 
showing the validity of the murine model system. Clinical studies 
report a higher response rate for continuous infusion than for 
bolus injections, but the overall results in terms of survival are 
not different. The plasma and tumour concentrations in mice 
are in the range of the concentrations which cause cell killing in 
r&o [ 111. In a cell line derived from Colon 26, C26- 10, the lcso 
for 5-FU, 72 h exposure, was 0.6 FM, at which a significant TS 
inhibition was observed. It should be noted that at longer 
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Figure 5. S-FU concentration in Colon 26 tumour tissue (mean 
values + S.D. of %5 tumours), 1 g of tissue was considered to be 
equivalent to 1 ml. Student’s t-test for paired data: 5-FU concen- 
tration in tumours was signiticantfy higher than plasma concentration 
on days 4 and 8 (P ~0.01). 
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Figure 6. (a) FdUMP binding to TS in Colon 26 tumours at different 
time points after pellet (10 mg S-FU) implantation. Control (open 
bars), free FdUMP binding sites after treatment, measured without 
dissociation (closed bars), total FdUMP biding sites after treatment 
measured after dissociation of samples (hatched bars). Values are 
means of at least 3 tumours 2 S.D. Student’s t-test unpaired data: at 
4,7 (P <O.OOl) and 11 days (P cO.05) after the start of 5-FU treatment 
the total FdUMP binding was significantly lower than control. A 
significant difference between the number of free biding sites and 
total binding sites was only observed at day 12 (P <O.Ol). (b) TS 
catalytic activity of Colon 26 tumours at different time points after 
whet (10 ma S-FU) imnlantation. Control (own bars). residual TS * . _ ,, 
cataly&c ackity after treatment, measured without dissociation 
(closed bars), total catalytic activity after treatment measured after 
dissociation of samples (hatched bars). Values are means of at least 
3 tumours + S.D. Student’s t-test unpaired data: no significant 
differences were observed between residual and total TS catalytic 
activity, but the total TS catalytic acticity on days 11,12 and 14 was 
significantly higher than the control value (P <O.OOl). 
incubations in z&o the lcso values for 5-FU decreased. Our in 
tivo results demonstrate that continuous infusion was more 
effective than bolus treatment in the initial inhibition of tumour 
growth, but this did not lead to a longer survival of the animals. 
From the concentration versus time plot it appeared that the 
profile of 5-FU concentrations in plasma was comparable to that 
observed in patients, but very different from that of bolus 
injections in which peak concentrations between 500 FM and 
1 mM are observed. The somewhat higher concentration just 
after the implantation of the pellet (0.2 p.M compared with 
0.05-O. 1 +M at later time points) was possibly due to the process 
by which pellets start to release the drug before reaching a stable 
rate of delivery. Only after 16 days did we observe a significant 
decrease in plasma levels. The increase in FdUMP binding sites 
in tumours, the rebound in blood cells and the increased rate of 
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tumour growth were already observed on day 7, well before the 
decrease in plasma and tissue levels of 5-FU. The small trough 
apparently present after 10 days was not significant. Exhaustion 
of the pellet is unlikely at that time point since animals that 
received pellets that had been implanted in different mice for 10 
days showed similar plasma concentrations of S-FU (Figure 4a). 
Variations in plasma concentration could also be due to changes 
in metabolism. These may consist of an increase in the activity 
of catabolising enzymes with time resulting in decreased plasma 
S-FU levels despite a regular delivery from the pellet. These 
changes in 5-FU plasma concentrations, however, were smaller 
than the variations observed during continuous infusion using 
pumps in patients [40]. Owing to these variables we did not 
include a pharmacokinetic evaluation. More extensive sampling 
would be required for a proper pharmacokinetic evaluation, and 
this would be impossible in the same mouse both for ethical an 
methodological reasons. 
Plasma 5-FU concentrations measured at 3 HALO corre- 
sponded to the values seen in the animals sampled over the entire 
3 weeks. Plasma samples obtained at later points of the day show 
that 5-FU concentrations increased to reach a peak at 6 HALO, 
followed by a decline. These data are in agreement with the 
circadian rhythm of DPD observed in rat liver [21] which is 
the main tissue responsible for 5-FU elimination [ 1, 21. The 
variation in enzyme activities is possibly related to the different 
antitumour activity of 5-FU when the drug is administered at 
different time points [41] and to the presence of varying 5-FU 
plasma concentrations during continuous infusion in patients 
[ 181. These concepts are currently being explored in the clinic 
and “chronomodulated ” delivery of 5-FU and of other drugs is 
becoming increasingly popular [24, 4241. 
In terms of dose delivered, continuous infusions offered a 
higher dose intensity than bolus injections. The total amount of 
drug administered was 10 mg versus 6 mg. This was comparable 
with the higher dose of 5-FU that can be given to patients with 
continuous infusion using schedules varying from 3 days to 
several weeks [7, 8, 33-381. 
The pattern of haematological toxicity induced by continuous 
infusion was quite different from what was observed with bolus 
injections. Nadir values observed after bolus injections were 
lower in the same strain ofmice (20%) [28, 291, but were reached 
later, while the rebound was lower and only observed after 
discontinuation of the treatment. In continuous infusion the 
rebound was even observed during infusion which would indi- 
cate that the low concentration of 5-FU might affect differen- 
tiation/proliferation of primitive stem cells. Evidence has indeed 
been obtained that low 5-FlJ concentrations can be immuno- 
stimulating [45] and the analysis of blood smears indicated that 
granulocytes were more affected than lymphocytes (data not 
shown). Different effects were also observed for the haematocrit 
(more severe after bolus injections). The data correspond to the 
observed lack of myeloid toxicity in the clinic with protracted 
infusion of 5-FU [7-91. 
In contrast to the haematological toxicity, weight loss at the 
MTD was maximal 11 days after pellet implant, much later than 
what was observed with bolu:j injections [28]. This difference in 
the time course of systemic toxicity was particularly evident 
when, during the determination of the MTD, mice were treated 
with doses of 5-FU that proved lethal. When an excessive dose 
was given as an infusion, weight loss was rapid and death 
occurred within 1 week (Fllgure 1). This is consistent with 
experimental and clinical observations on the different toxicity 
seen after bolus or infusional administration of 5-FU: mainly 
haematological for bolus treatment, gastrointestinal for 
infusions. We have observed that a bolus injection of 5-FU can 
inhibit TS in mucosal tissue [46] and the prolonged presence of 
5-FU might be particularly toxic to gastrointestinal tissues. 
LV administration enhanced the gastrointestinal toxicity of 
infusional 5-FU, suggesting that TS inhibition was involved. 
The continuous, repeated administration of LV possibly pro- 
vided enough folates in these normal tissues in order to enhance 
this inhibition, despite the low activity of folylpolyglutamate 
synthetase in these tissues [47]. The importance of this enzyme 
in resistance to the continuous exposure to 5-FU has also 
been reported for tumour cells [48]. Results on gastrointestinal 
toxicity are consistent with the clinical observations: patients 
receiving LV, even at very low daily doses (5 mg/day p.o.) 
[33, 49-521 have a marked increase of toxicity during continuous 
infusion of 5-FU. In addition, in several clinical trials modulation 
of continuous infusion 5-FU with LV did not increase the 
antitumour activity [33] similar to our murine study, in which 
no schedule of LV administration improved the therapeutic 
effect. 
The pattern of antitumour activity of continuous infusion was 
different from that obtained with bolus injections even if overall 
results were similar. While bolus injections only reduced the 
growth rate, continuous infusion actually blocked tumour 
enlargement for Colon 26 (for approximately 1 week) and after 
this time tumour growth resumed at the same rate as untreated 
controls. This time course was seen in all the experiments 
performed with continuous infusion, with or without LV, and 
could also be seen when a smaller pellet of 5 mg was implanted. 
In this last case, however, tumour growth was blocked for only 
3 days. For Colon 38, a significant reduction in tumour size was 
observed. These results are consistent with clinical observations 
in which continuous infusion is reported to be associated with a 
higher response rate, but not with an increased survival [7, 81 
compared with bolus. 
Interestingly, a low FdUMP was associated with an almost 
total inhibition of TS activity, similarly to what has been 
observed in patients [53]. The growth of tumours went along 
with an increase in TS activity that occurred despite the suf- 
ficiently high concentration of 5-FU in plasma and in tissues to 
inhibit cell growth and TS activity in vitro [ 151. The increase in 
TS indicates that this enzyme is a key target for the activity of 
continuous infusion 5-FU, in agreement with in vitro results 
[16]. An increase in TS was also an important mechanism of 
resistance to bolus injections of 5-FU in the same model [17], 
and a similar increase in TS activity has been observed after in 
vitro exposure to 5-FU [54]. Current strategies are directed at 
preventing the increase in TS; we have recently demonstrated 
that this effect can be obtained in Colon 26 with LV adminis- 
tration [17]. Whether this feedback regulation is similar to 
that reported for interferon y [54] remains to be proven. 
Unfortunately, in our system the antitumour activity of continu- 
ous infusion was not improved by any combination with LV, 
which is consistent with in vitro observations that LV only 
marginally increased the duration of TS inhibition during con- 
tinuous exposure of cells to 5-FU [16]. This modulation was 
also hampered by the increase in gastrointestinal toxicity. The 
current model seems to be useful to study the activity of 5-FU 
given as a continuous infusion in mice and to investigate the 
association with modulating agents such as interferons. 
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